TuHURA Biosciences Progresses with Kineta Acquisition
Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody to TuHURA's late-stage immuno-oncology pipeline.
TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in upcoming years.
Completion of the acquisition unlocks significant funding from previously announced financing.
About the Acquisition
TuHURA Biosciences, Inc. (NASDAQ: HURA), a company focused on innovative immuno-oncology solutions, proudly announces the successful acquisition of Kineta, Inc. Through this strategic move, TuHURA incorporates a Phase 2 ready monoclonal antibody, now referred to as TBS-2025. This groundbreaking asset aims to tackle acquired immunotherapy resistance in various cancers.
According to James Bianco, M.D., President and CEO of TuHURA, this acquisition bolsters their existing pipeline by introducing a promising candidate capable of overcoming cancer’s resistance mechanisms.
Drug Development Pipeline Expansion
While TuHURA continues to advance its innate immune agonist, IFx-2.0, which is undergoing evaluation in Merkel cell carcinoma, the addition of TBS-2025 opens new avenues for targeted therapies. Clinical strategies are being developed to assess the combined effects of TBS-2025 with other treatments, especially in patients where conventional therapies have fallen short.
TBS-2025 targets VISTA, a crucial immune checkpoint evident in myeloid cells and T cells, which plays a significant role in tumor-induced immune suppression. Research indicates that targeting VISTA can rejuvenate immune responses against cancer cells.
Future Clinical Trials
Plans are underway for a Phase 2 trial of TBS-2025 in conjunction with a menin inhibitor for patients with NPM1 mutated AML. Given that VISTA is primarily present in MDSCs and quiescent T cells, this approach seeks to diminish immune evasion tactics employed by leukemic cells.
Notably, target mutations in AML, including NPM1 and DNM3TA, have been linked to heightened VISTA expression, reinforcing the need for effective monoclonal antibodies like TBS-2025. The anticipation is that this small-scale trial will illuminate potential enhancements in treatment efficacy and reduced relapse rates.
Transaction Highlights
Under the merger agreement, Kineta shareholders receive 0.185298 shares of TuHURA Common Stock for each Kineta share. The agreement also includes potential cash considerations from the sale of Kineta's legacy assets to be paid later, making this merger beneficial for both parties.
About TBS-2025 (formerly KVA12123)
TBS-2025 represents a significant advancement in immunotherapy, formulated to enhance the immune system's ability to recognize and battle cancer cells. Administered bi-weekly, this engineered IgG1 monoclonal antibody showcases a promising safety profile, having been well tolerated in early-phase studies.
Results from Phase 1/2 trials indicate notable pharmacokinetic efficacy and consistent immune modulation, providing hope for patients facing limited treatment options.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (NASDAQ: HURA) continues to pioneer research in immuno-oncology, driven by innovative technologies aimed at overcoming resistance to current therapies. With a notable focus on unique drug conjugates and immune system modulation, TuHURA is dedicated to enhancing the effectiveness of cancer treatments.
TuHURA's lead candidate, IFx-2.0, is specifically designed to work synergistically with existing cancer therapies, promoting more effective treatment pathways against various cancers.
For detailed information about TuHURA and its initiatives, please visit www.tuhurabio.com.
Frequently Asked Questions
What is TBS-2025?
TBS-2025 is a VISTA inhibiting monoclonal antibody acquired by TuHURA Biosciences that targets immune suppression mechanisms in cancer therapy.
When will clinical trials for TBS-2025 start?
TuHURA plans to initiate Phase 2 clinical trials involving TBS-2025 in a randomized fashion within the next few years.
How does TBS-2025 work?
TBS-2025 works by blocking VISTA, an immune checkpoint that hinders T cell activation, thereby enhancing the body’s ability to fight cancer.
What is the significance of the Kineta acquisition?
The acquisition of Kineta enables TuHURA to expand its pipeline, providing access to novel therapies ready for advanced clinical stages.
What are TuHURA's future goals?
TuHURA aims to innovate in immuno-oncology by focusing on developing effective therapies that can synergize with existing treatments to overcome resistance in cancer patients.
